Lunit

328130.KQ

24.71 USD

-0.57

-2.25%

Overview

Last close

24.71 usd

Market cap

720.16M usd

52 week high

58.23 usd

52 week low

23.39 usd

Target price

33.39 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

13.7592

Price/Book Value

6.5583

Enterprise Value

784.65M usd

EV/Revenue

15.0122

EV/EBITDA

-45.3273

Key financials

Revenue TTM

50.36M usd

Gross Profit TTM

50.36M usd

EBITDA TTM

-45.71M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

277.89M usd

Net debt

43.87M usd

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations and with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.